Stem Cell Therapy for Motor Neuron Disease

Stem cell therapy for ALS and PLS has been studied in clinical trials for more than a decade. The current state of the evidence is this: no stem cell therapy has been approved for ALS or PLS anywhere in the world. Some approaches have demonstrated safety and early biological signals in Phase 1 and Phase 2 trials. Others have been inconclusive. And a substantial industry of unregulated clinics offers unproven stem cell treatments to patients, for large fees, outside of any research framework. This page covers all of it honestly.

The theory behind stem cell therapy in MND

Motor neuron disease involves the progressive death of motor neurons — the nerve cells that control voluntary movement. In ALS, both upper motor neurons (in the motor cortex and corticospinal tract) and lower motor neurons (in the spinal cord and brainstem) degenerate. In PLS, the degeneration is predominantly in upper motor neurons. The question stem cell researchers have been asking is: can transplanted cells survive in the diseased nervous system long enough to provide meaningful benefit?

There are several ways transplanted cells might help. They can act as sources of neuroprotective growth factors — particularly GDNF (glial cell line-derived neurotrophic factor), BDNF (brain-derived neurotrophic factor), and VEGF (vascular endothelial growth factor) — that support the survival of existing motor neurons. They can modulate the immune and inflammatory environment around degenerating neurons, potentially slowing the disease process. In principle, they might also replace lost support cells such as astrocytes or oligodendrocytes. True replacement of lost motor neurons — replacing the neurons themselves — is a much more distant goal, because transplanted neurons would need to form functional connections with muscle targets, which is technically very difficult.

Most clinical programs to date have aimed at the first two goals: neuroprotection and immunomodulation, not cell replacement.

The three main cell approaches

Mesenchymal stem cells (MSCs)

Mesenchymal stem cells are multipotent stromal cells that can be derived from bone marrow, adipose (fat) tissue, or umbilical cord blood. They are relatively accessible, can be derived from the patient (autologous) to reduce immune rejection risk, and have known anti-inflammatory properties. They can be delivered intrathecally (into the CSF) or intravenously.

MSCs have been the most extensively studied cell type in ALS clinical trials. A 2021 meta-analysis (Nature npj Regenerative Medicine) analyzed 11 studies involving 220 cell-treated ALS patients and found that intrathecal MSC delivery produced a transient positive effect on ALSFRS-R scores — but was associated with worsening of forced vital capacity (lung function) after all interventions. The authors concluded that the optimal cell product and route of administration need further determination in controlled preclinical models before further advancement. This is a fair summary of where MSC therapy in ALS stands: signals of biological activity, but no consistent evidence of clinical benefit, and some safety signals that require explanation.

Neural stem cells and neural progenitor cells (NSCs/NPCs)

Neural stem cells and their more committed progeny, neural progenitor cells, are derived from neural tissue and are specifically designed to function in the nervous system. They are more neurologically relevant than MSCs but harder to source and manufacture at clinical scale. The leading clinical program in this category is the Cedars-Sinai CNS10-NPC-GDNF approach.

The CNS10-NPC-GDNF cells are human neural progenitor cells that have been genetically engineered to secrete GDNF — a powerful neurotrophic factor that supports motor neuron survival. The approach combines stem cell therapy with gene therapy: the cells act as living delivery vehicles for GDNF, providing sustained local growth factor delivery to the spinal cord.

A Phase 1/2a trial at Cedars-Sinai — published in Nature Medicine in 2022 — evaluated this approach in patients with ALS. The transplantation was done via direct intraspinal injection (surgical delivery into the spinal cord), which is more invasive than intrathecal delivery but ensures cells reach the target area. The Phase 1/2a trial demonstrated safety and tolerability as a primary endpoint, with early signals of biological activity. This was an important advance: it showed the approach was feasible and safe at clinical scale.

Evidence level for CNS10-NPC-GDNF: Limited — Phase 1/2a safety data, positive biological signals, no controlled efficacy data yet.

Induced pluripotent stem cells (iPSCs)

Induced pluripotent stem cells are adult cells (typically skin or blood cells) that have been reprogrammed back to a pluripotent state — capable of becoming any cell type in the body. Patient-derived iPSCs can then be directed to differentiate into motor neurons, allowing researchers to study that patient's motor neurons in a dish.

iPSCs have two main applications in MND research. The first is direct therapeutic use — transplanting iPSC-derived cells into patients. The second, arguably more immediately productive application, is as a drug discovery platform: screening hundreds of compounds against patient-derived motor neurons in the lab to identify potential therapeutics before moving to animal models or human trials.

A landmark paper in Nature Neuroscience (November 2025) used iPSC-derived motor neurons from sporadic ALS patients to screen hundreds of compounds at large scale, identifying a potential combinatorial therapy approach — drug combinations that were more effective than single agents in maintaining motor neuron health. This work is important because sporadic ALS patient iPSCs capture the genetic heterogeneity of non-familial disease, making findings more broadly applicable.

Case Western researchers also used iPSCs from ALS patients with VAPB mutations to identify the Integrated Stress Response (ISR) as a therapeutic target, showing that ISR blockade reversed damage in laboratory models. This kind of iPSC-based research is helping to identify new drug targets that can then move into conventional drug trials.

Direct therapeutic use of iPSC-derived cells in human patients is still being developed. Open questions include optimal cell source (autologous versus allogeneic), delivery route, dosing, and management of immune rejection. No approved iPSC-derived cell therapy exists for MND.

What the meta-analysis evidence shows

Taking the published evidence across all cell types and delivery approaches, the 2021 meta-analysis provides the clearest summary: stem cell therapies in ALS have demonstrated safety and produced transient biological signals in some studies, but have not shown consistent or durable clinical benefit. The field is advancing — with better cell sources, manufacturing processes, and delivery methods — but it has not yet delivered a clinical success.

Key open questions the field needs to resolve include: which cell type is optimal for MND? What is the best delivery route (intrathecal, intraspinal, intravenous, intramuscular)? What dose is needed? How often should treatment be given? How do we manage immune rejection of allogeneic cells? These are substantial questions and their answers will require well-designed controlled trials.

Current status for PLS specifically

No stem cell clinical trial has specifically enrolled PLS patients, to our knowledge. The existing trial data comes from ALS populations. The relevant biology differs in important ways: PLS involves upper motor neuron degeneration in the motor cortex and corticospinal tract, while most ALS stem cell trials have focused on spinal cord delivery targeting lower motor neurons. An approach designed for spinal cord delivery would need to be adapted for cortical delivery to be directly relevant to PLS — a different and technically more challenging problem.

Whether neuroprotective growth factor delivery to the spinal cord (as with CNS10-NPC-GDNF) could slow upper motor neuron degeneration indirectly through corticospinal pathway support is theoretically interesting but has not been studied. PLS patients interested in stem cell approaches have no current trial option, and the existing trials that produce safety data are not applicable to PLS biology without further investigation.

The serious problem of unregulated stem cell clinics

How to think about this area

Stem cell therapy for motor neuron disease is a legitimate and active area of research. The Cedars-Sinai program, the iPSC drug screening work at Case Western, and the ongoing refinement of cell manufacturing and delivery approaches are real science conducted by serious researchers. The field is making progress.

What it is not is a current treatment option. Phase 1/2a data that demonstrates safety is a starting point, not a proof that the treatment works. The gap between "safe" and "effective" in clinical research is large, and most therapies that clear early-phase safety trials still fail to demonstrate efficacy in controlled studies.

If you are interested in stem cell research specifically, the most productive path is to ask your neurologist whether any cell therapy trials are currently enrolling patients with PLS or UMN-predominant MND, and to monitor ClinicalTrials.gov for new registrations in this area. Participating in legitimate trials is both the safest way to access experimental therapies and the way to contribute directly to the evidence base.